Radiopharmacy is our passion
Bridging preclinical research and clinical development to accelerate the clinical implementation of unique cancer diagnostics and therapeutics for the long term benefit of cancer patients.
About UsBridging preclinical research and clinical development to accelerate the clinical implementation of unique cancer diagnostics and therapeutics for the long term benefit of cancer patients.
About UsSCINTOMICS has a constantly developing and evolving portfolio of unique radiopharmaceuticals and paves the way for clinical development for such Theranostic. We are proud of the fact that several radiopharmaceuticals from our portfolio are currently developed in clinical studies or on the way to market approval in the near future. The certainty that these developments will open up new avenues for the diagnosis and therapy of cancer patients is a great motivation for us to continue mission with great commitment and enthusiasm.
Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer
Read morePOINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer.
Read moreFeburary 6th 2020, WÜRZBURG, Germany--PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
Read more